 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 08/13/2010 | | | | Nymox Reports Second Quarter 2010 Financial Results
topic: Financial
August 13, 2010: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today its financial results for the second quarter of 2010. |
| 07/28/2010 | | | | Nymox Reports Safety Monitoring Committee Findings For Pivotal Phase 3 NX-1207 Trials
topic: R&D: BPH (enlarged prostate) Treatments
July 28, 2010: Nymox provided an update
today on the Company’s Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. |
| 07/21/2010 | | | | Singular Research Initiates Coverage of Nymox with “Buy” Rating
topic: Financial
July 21, 2010: Singular Research has initiated coverage of Nymox Pharmaceutical
Corporation (NASDAQ: NYMX) with a “Buy” rating and a 12 month target price of $11.00. According to the report, “Nymox Pharmaceutical is a
pharmaceutical development company with a very promising compound for enlarged prostate that is in Phase 3 clinical
trials…several anticipated events in the coming 12 to 18 months will lead to greater investor awareness of the product and
push valuations upwards, in our opinion”. |
| 07/07/2010 | | | | Nymox Reports Positive New Clinical Trial Data on Improvement in Key Symptom in Patients on NX-1207 Drug for Prostate Enlargement
topic: R&D: BPH (enlarged prostate) Treatments
July 7, 2010: Nymox reported
today positive new results from pooled analysis of completed clinical trials of NX-1207, the Company’s
investigational drug for BPH. The trial data shows that patients receiving NX-1207 recorded significant
quantitative improvement in the important symptom of urgent need to urinate. |
| 06/22/2010 | | | | Nymox Announces New U.S. Follow-Up Results From Study NX02-0014, BPH Drug NX-1207 Continues to Show Positive Data at 5 Years
topic: R&D: BPH (enlarged prostate) Treatments
June 22, 2010: Nymox reports positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. |
| 06/15/2010 | | | | Nymox Reports Near Completion of New Five Year Long-Term Follow-Up NX02-0014 U.S. Study of BPH Drug
topic: R&D: BPH (enlarged prostate) Treatments
June 15, 2010: Nymox announced today that the Company is nearing completion of a new multi-center U.S. long-term followup study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH).
The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207 for patients who participated in Nymox’s U.S. Study NX02-0014 in 2005-2006. |
| 06/07/2010 | | | | Nymox to Present at Jefferies 2010 Global Life Sciences Conference
topic: Financial
June 7, 2010: Nymox announced
today that Paul Averback, MD, DABP, President and Chief Executive Officer of Nymox, will be providing a
corporate summary and a presentation regarding the Company’s ongoing clinical program for NX-1207 at the
Jefferies 2010 Global Life Sciences Conference in New York on June 9, 2010. |
| 06/02/2010 | | | | New Positive Data on NX-1207 Presented at Symposium at American Urological Association Annual Meeting
topic: R&D: BPH (enlarged prostate) Treatments
June 2, 2010: Nymox is pleased to
report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. |
| 05/25/2010 | | | | Nymox Announces 3 Year Follow-Up Results From NX02-0016 U.S. Study of NX-1207 for BPH
topic: R&D: BPH (enlarged prostate) Treatments
May 25, 2010: Nymox reports positive new results from the 30-36 month follow-up study of patients treated with NX-1207 in Study NX02-0016. |
| 05/20/2010 | | | | Symposium on Nymox’s NX-1207 BPH Drug To Be Held at Annual Meeting of American Urological Association in San Francisco
topic: R&D: BPH (enlarged prostate) Treatments
May 20, 2010: Nymox is pleased to announce that a symposium and panel discussion devoted to progress in the development of NX-1207, the Company’s Phase 3 drug for benign prostatic hyperplasia (BPH), will be held at the 2010 Annual Meeting of the American Urological Association which begins May 29 in San Francisco. |
|